Cultivar variation for imazamox resistance in wheat (Triticum aestivum L.) : Insights into enzymatic assays for early selection

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Détails bibliographiques
Publié dans:Plant physiology and biochemistry : PPB. - 1991. - 151(2020) vom: 01. Juni, Seite 438-442
Auteur principal: Breccia, Gabriela (Auteur)
Autres auteurs: Picardi, Liliana, Nestares, Graciela
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Plant physiology and biochemistry : PPB
Sujets:Journal Article Acetohydroxyacid synthase Dose-response curves Herbicide resistance Imidazolinone In vitro AHAS activity In vivo AHAS activity Herbicides Imidazoles Acetolactate Synthase plus... EC 2.2.1.6 imazamox UG6793ON5F
Description
Résumé:Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Acetohydroxyacid synthase (AHAS, E.C. 2.2.1.6) is the target site of several herbicide classes including imidazolinones. Imidazolinone resistance in wheat is conferred by two major genes AhasL-D1 and AhasL-B1. The objective of this work was to evaluate the in vitro and in vivo AHAS activity and plant growth in response to imazamox of nine wheat cultivars. Dose-response curves for two-gene resistant cultivars were significantly different from the single-gene resistant and susceptible cultivars in the in vitro AHAS assay. Resistance levels at the in vivo AHAS and whole-plant assays for resistant cultivars were >10-fold higher than susceptible cultivars. Moreover, in vivo dose-response curves showed differences among cultivars with the same number of resistance genes. It was concluded that in the in vitro AHAS assay cultivar variability was due to differences in target-site sensitivity while the in vivo AHAS assay reflected the resistance at whole-plant level. Both in vitro and in vivo AHAS dose-response curves could be useful tools when exploring mechanisms involved in imidazolinone resistance in different wheat genetic backgrounds and for the selection of higher resistant genotypes
Description:Date Completed 28.07.2020
Date Revised 30.09.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1873-2690
DOI:10.1016/j.plaphy.2020.03.045